- Lonza opens its new Innovaform Accelerator at the Colmar site in France to advance capsule-based drug delivery solutions.
- The facility will focus on enhancing solubility and bioavailability challenges for oral and pulmonary drug administration.
Lonza has officially opened its Innovaform Accelerator at its Colmar site in France, a new centre aimed at improving capsule-based manufacturing and delivery for oral and pulmonary drug administration. The facility will serve as a Centre of Excellence, helping drug developers tackle solubility and bioavailability challenges, which often affect absorption in the gastrointestinal tract.
The Innovaform Accelerator targets small molecules but also extends to oral peptides, proteins, monoclonal antibodies, and nucleic acid-based therapeutics. It offers solutions for improving the solubility of active pharmaceutical ingredients (APIs) and customizing capsule formulations to ensure precise drug release.
The facility will provide a range of services, including formulation development, capsule customization, and scale-up manufacturing assessments. These services aim to help pharmaceutical companies move their products from development to production more efficiently.
“The Innovaform Innovation and Formulation Accelerator represents a unique solution for drug developers seeking to solve complex dosage form and delivery challenges through innovation,” said Christian Seufert, President, Capsules & Health Ingredients at Lonza. He added that the new facility would help accelerate development timelines while reducing costs.
Overview of outsourcing trends 
